Revive Therapeutics Company Description

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders.

It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.

The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases.

Revive Therapeutics Ltd. is based in Toronto, Canada.